Drugging the ‘undruggable’ cancer targets

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Selective inhibition of BET bromodomains

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262

MYC on the Path to Cancer

Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390

Peptide therapeutics: current status and future directions

Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557

Drugging the undruggable RAS: Mission Possible?

Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536

Nonsurgical Management of Cholangiocarcinoma

Breen, M. J., Ahmed, O. S., Owen, J., & Liao, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_16-1

γ-aminobutyrate (GAB) functions as a bioenergetic and signaling gatekeeper to control T cell inflammationPreprint

Kang, S., Liu, L., Wang, T., Cannon, M. V., Lin, P., Fan, T. W. ‐., Scott, D. A., Wu, H.-J. J., Lane, A. N., & Wang, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.17.480926

Protein Degradation Technology

高, 杰. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.101003

Targeting Positive Cofactor 4 Induces Autophagic Cell Death In MYC-Expressing Diffuse Large B Cell LymphomaPreprint

Ma, L., Gong, Q., Fu, J., Xie, M., Luo, P., Chen, J., & Shi, C. (2021) · Research Square · doi:10.21203/rs.3.rs-421070/v2

Nanotechnology Application in tissue regeneration and gene therapy

Shanko, A., Kumar, D., Prashar, D. D., rawat, N., Negi, P., & Sharma, S. K. (2022) · YMER Digital · doi:10.37896/ymer21.05/21

Total Synthesis and Chemoproteomics Connect Curcusone Diterpenes with Oncogenic Protein BRAT1Preprint

Cui, C., Dwyer, B. G., Liu, C., Abegg, D., Cai, Z., Hoch, D. G., Yin, X., Qiu, N., Liu, J., Adibekian, A., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.13271702

MicroRNA-708 emerges as a potential candidate to target undruggable NRASPreprint

Lin, K., Pang, J. M., Chien, P.-C., Kao, M.-C., Chiu, P.-Y., Chen, P.-X., Hsu, Y.-L., Liu, C., & Liang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1954766/v1

Applications of nuclear magnetic resonance spectroscopy: from drug discovery to protein structure and dynamics.

Cerna, M. V. C. D. (2022) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3946

Deubiquitinating Enzymes

Liu, X., Doherty, L. M., Felix, A., & Buhrlage, S. J. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch7

Data from Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death

Cottone, L., Cribbs, A. P., Khandelwal, G., Wells, G., Ligammari, L., Philpott, M., Tumber, A., Lombard, P., Hookway, E. S., Szommer, T., et al. (2023) · doi:10.1158/0008-5472.c.6512377

Data from Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death

Cottone, L., Cribbs, A. P., Khandelwal, G., Wells, G., Ligammari, L., Philpott, M., Tumber, A., Lombard, P., Hookway, E. S., Szommer, T., et al. (2023) · doi:10.1158/0008-5472.c.6512377.v1

Data from Insights into the Links between MYC and 3D Chromatin Structure and Epigenetics Regulation: Implications for Cancer Therapy

Amjadi‐Moheb, F., Paniri, A., & Akhavan‐Niaki, H. (2023) · doi:10.1158/0008-5472.c.6512979.v1

Data from Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Salem, A. H., Tao, Z., Bueno, O. F., Chen, J., Chen, S., Edalji, R. P., Elmore, S. W., Fournier, K. M., Harper, K. C., Hong, R., et al. (2023) · doi:10.1158/1535-7163.c.6543327.v1

Data from Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Salem, A. H., Tao, Z., Bueno, O. F., Chen, J., Chen, S., Edalji, R. P., Elmore, S. W., Fournier, K. M., Harper, K. C., Hong, R., et al. (2023) · doi:10.1158/1535-7163.c.6543327

Targeting RNA with Small Molecules

Zhang, P., Bush, J. A., Childs‐Disney, J. L., & Disney, M. D. (2023) · Springer eBooks · doi:10.1007/978-981-16-1313-5_96-1

Cell state-dependent chromatin targeting in NUT carcinoma

Alekseyenko, A. A., Zee, B. M., Dhoondia, Z., Kang, H., Makofske, J. L., & Kuroda, M. I. (2023) · Genetics · doi:10.1093/genetics/iyad083

Inhibition of CDK4 as a potential therapy for natural killer cell lymphoma with MYC overexpressionPreprint

Huang, Y., Ali, R., Wang, F., Yang, X., Bouska, A. C., Lunning, M. A., Chan, W. C., Iqbal, J., Weisenburger, D. D., Vose, J. M., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3011981/v1

Identification of putative druggable pockets in PRL3, a significant oncology target, using in silico analysisPreprint

Bennett, G. M., Starczewski, J., & Cerna, M. V. C. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.31.551065

The permissive binding theory of cancer

Weisman, C. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1272981

Molecular characterization of FOX factors and Wnt signalling interplay in human cancers

Pizzolato, G. (2023) · Linköping University medical dissertations · doi:10.3384/9789180753364

MicroRNA-508-3p regulates the proliferation of human lung cancer cells by targeting G1 to S phase transition 1 (GSPT1) protein

Chen, X., Feng, C., Zha, J., Shen, Z., & Ji, W. (2023) · Acta Biochimica Polonica · doi:10.18388/abp.2020_6660

Pharmacokinetics, Tissue Distribution, and Formulation Study of a Small-molecule Inhibitor of MKLP2, LG157Preprint

Choudhry, N., Li, J., Zhang, T., Chenyu, J., Zhou, X., Shi, Q., Lv, G., & Yang, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.25.573327

Additional file 18 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001023

Additional file 14 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001011

Additional file 15 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001014

Additional file 13 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001008

Additional file 16 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001017

Additional file 20 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001032

Additional file 17 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001020

Additional file 19 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001026

Multifaceted perspectives of detecting and targeting solid tumors

Bhattacharya, A., & Dasgupta, A. K. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.03.010

The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs)

Zhang, L., Deng, T., Liufu, Z., Liu, X., Chen, B., Hu, Z., Liu, C., Tracy, M. E., Lu, X., Wen, H., et al. (2024) · eLife · doi:10.7554/elife.99340.3

Unraveling the folding-assisted unbinding mechanism of TCF with its binding partner β-catenin

Vijay, A., & Mukherjee, A. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp01451k

Structures of the human transcription factor brachyury offer insights into DNA recognition, and identify small molecule binders for the development of degraders for cancer therapyPreprint

Newman, J. A., Gavard, A. E., Imprachim, N., Aitkenhead, H., Sheppard, H. E., Clarke, P. A., Hossain, M. A., Temme, L., Oh, H. J., Wells, C. I., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.06.597736

Atomic-scale mechanisms of GDP extraction by SOS1 in KRAS-G12 and KRAS-D12 oncogenesPreprint

Hu, Z., & Martı́, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.17.599303

Pre‐mRNA Splicing Modulation

Barraza, S. J., & Woll, M. G. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch7

In silico fragment-based design and pharmacophore modelling of therapeutics against dengue virus envelope protein

Chaudhuri, D., Majumder, S., Datta, J., & Giri, K. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00262-9

Emerging Technologies for Epigenetic Drug Discovery

(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part2

Mass Spectrometry and Chemical Biology Approaches for Deconvoluting Epigenetic Targets

Burton, A. J., Hamza, G. M., Iannetta, A. A., Miele, E., & Zhang, A. X. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00050

A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcomaPreprint

Santos, M. A. I. C. D. L., Gloege, H. F., Shen, M., Heaslip, C., Aguilar-Quintero, A. E., McDannell, B., Tanhaemami, M., Meyer, S. C., Klega, K. S., Zhang, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618327

Structure-Activity Relationship Studies and Design of a Ptpn22 Inhibitor with Enhanced Isozyme Selectivity and Cellular EfficacyPreprint

Zhang, Z., Jassim, B. A., Bai, Y., Qu, Z., Sander, C. J., Lin, J., & Miao, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4992070

Multi‐Specific Binding Strategy

Zhou, Y., Xu, S., Ding, D., Tang, K., Liu, X., Kim, M., & Zhan, P. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch11

Five Key Criteria for Identifying Optimal Therapeutic Targets in Protein‐Mediated Diseases

Al‐Shuhaib, M. B. S., & Al‐Shuhaib, J. M. B. (2025) · ChemistrySelect · doi:10.1002/slct.202403409

PepTune: De Novo Generation of Therapeutic Peptides with Multi-Objective-Guided Discrete Diffusion.Preprint

Tang, S., Zhang, Y., & Chatterjee, P. (2025) · PubMed

Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis

Bi, Q., Nie, J. H., Wu, Q., Sun, L., Zhu, S., Bai, J., Liu, Y. U., Huang, F., & Chai, K. (2025) · Medical Oncology · doi:10.1007/s12032-025-02604-9

Restoration of tumor suppressor protein with enhanced activity using super-tRNAs to induce tumor regressionPreprint

Kong, B., Zheng, Z., Mi, Z., Dou, Z., Yang, Y., Shen, Y., Dong, L., Lv, J., Li, Y., Liang, Q. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643282

Conformational mapping of GPCR activation: dynamic allosteric site discovery in V2R through MD-MSM and mutual information analysisPreprint

Lu, S., Qiao, X., Zhu, C., Lan, X., Li, M., Li, N., Huang, J., Liu, N., & Zhang, J. (2025) · Research Square · doi:10.21203/rs.3.rs-6427090/v1

Mechanism and cytotoxicity of A1874 proteolysis targeting chimera on CT26 colon carcinoma cell line

Shin, J., & Shin, S. (2025) · Journal of Emerging Investigators · doi:10.59720/24-330

Improving the Cellular Accumulation of Folate-Conjugated Fully Chemically Modified siRNAs via 3′ Terminal Conjugation

Motosawa, K., Iwano, J., Harumoto, T., Yabuuchi, H., Hatanaka, K., Koda, Y., Kubo, T., Kodaira, H., & Uehara, K. (2025) · ACS Omega · doi:10.1021/acsomega.4c11519

JAK2 Inhibitors as the Elixir for Humans: A Truth or Myth (A Review)

Achutha, A. S., Pushpa, V. L., Divya, V., Sarithamol, S., Surendran, S., Manoj, K. B., Sunitha, V. R., & Jeneena, K. B. (2025) · Cell and Tissue Biology · doi:10.1134/s1990519x25600097

Oxidant‐Triggered Bioconjugation Chemistry: Expanding the Landscape of Ligandable Lysine Residues in the Proteome

Li, S., Zhou, M., Huang, W., Yuan, X., Jin, W., & Li, Z. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202502153

Bacterial Display of Genetically Encoded Macrocyclic Peptide Libraries Using Cysteine-Reactive Unnatural Amino Acids

Dawodu, O., & Tharp, J. M. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00634

Combined inhibition of CDK4/6 and PI3K pathways exhibit highly synergistic activity and translational potential in Ewing sarcoma

Gloege, H. F., Santos, M. A. I. C. D. L., Chakraborty, A., Chadha, M., Aguilar-Quintero, A. E., Shen, M., Heaslip, C., Finstuen-Magro, S., McDannell, B., Tanhaemami, M., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102866 · Cited by 1

The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment

Cui, Y., Yang, W., Liu, W., Li, Y., Yu, C., Yu, C., Liu, Y., Xu, D., & Zhu, X. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s526592

Additional file 9 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001059

Additional file 8 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001056

Additional file 1 of Computational models of melanoma

Albrecht, M., Lucarelli, P., Kulms, D., & Sauter, T. (2020) · Figshare · doi:10.6084/m9.figshare.12307859

Additional file 11 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001002

Additional file 6 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001050

Additional file 12 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001005

Additional file 5 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001047

Additional file 4 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001041

Additional file 7 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001053

Additional file 3 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001038

Additional file 10 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20000999

Additional file 2 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001035

Additional file 1 of Integrated proteogenomic characterization of urothelial carcinoma of the bladder

Xu, N., Yao, Z., Shang, G., Ye, D., Wang, H., Zhang, H., Qu, Y., Xu, F., Wang, Y., Qin, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20001029

Gezielte Modulation des spliceosomalen Proteins USP39 durch allosterische Liganden und PROTAC‐induzierte Degradation

Schäfer, D., Prieto‐Garcia, C., Wang, J., Heinz, M., Matković, V., Kielkowski, P., Hasselbeck, S., Shah, V. J., Knapp, S., Hummer, G., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202516809

Computational design of orthogonal TCR α/β interfaces for dual-TCR therapeuticsPreprint

Kinjo, T., Yu, S., Nicely, N. I., Leaver‐Fay, A., Kim, W., & Kuhlman, B. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697397

Research Advances in KRAS Mutation Cancer Treatment Strategies: From “Undruggable” Targets to Diversified Precision Therapies

朱, 含. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161317

Enhanced Sampling and Ligandability Assessment to Expand the Repertoire of Potentially Druggable Cryptic Pockets

Vithani, N., Zhang, S., Günther, J., Purkey, H. E., Lawson, J. D., Nicholls, A., Skillman, A. G., & LeBard, D. N. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c05778

BOND-PEP: topology-conditioned bipartite alignment for evidence-grounded peptide binder generationPreprint

Ding, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706554

Targeting MYC in T-Cell lymphoma via epigenetic modulation with a small-molecule inhibitor

Liu, B., Jiang, B., Liu, S., Zhang, S., Huang, Z., Zhang, M., Zhao, X., Li, Q., Li, X., Xia, J., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02640-7

Real time imaging of transcription reveals new features of cellular and viral promoters

Kozulic-Pirher, A. (2018) · theses.fr (ABES) · doi:10.70675/0099e36bz620ez43d7z9b47z2789ed360d73

A synthetic B-subunit of Shiga toxin with enhanced cytosolic delivery efficiency for innovative anticancer immunotherapies

Billet, A. (2021) · theses.fr (ABES) · doi:10.70675/4a52ead6z1793z40c3zbfdbzfc38b2258b75

Knowledge Discovery and Drug-Repurposing Framework for Pancreatic Ductal Adenocarcinoma: Molecular Networking and Computational Docking

Čorbo, T., Graarud, E. P., Resell, M., Kalajdžić, A., Pojskić, N., Chen, D., Gustafsson, B. I., & Zhao, C.-M. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0067

Design and synthesis of trisubstituted 1,2,4-triazoles : structural exploration in the inhibition of GSK-3β for the treatment of Alzheimer’s disease

Pereira, T. M. (2024) · theses.fr (ABES) · doi:10.70675/f501300bz5a57z477eza236z79f3a6d2a052

Comprendre et cibler la molécule intracellulaire "CISH" dans les cellules Natural Killer : une stratégie pour optimiser les traitements en immunothérapies

Bernard, P.-L. (2023) · theses.fr (ABES) · doi:10.70675/b8c6e6e6z06f4z4377z80e6z1bce4ed7771a

Network-Guided Identification of Plant-Derived Modulators of Stress-Adaptive Signalling in Neuroblastoma

Motshudi, M. C., Naidoo, C. M., Obi, C. L., Iweriebor, B. C., Prinsloo, E., Zubair, M. S., & Mkolo, N. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093739

Harnessing Targeted Protein Degradation for Developing Brain Cancer Therapy

Muhammad, O., White, S., Dumo, C. J., Park, T. I., Choi, P. J., & Jose, J. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00123

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugsPreprint

Nguyen, H. V., Michla, M., Yan, F., Davidson, N., Kelly, G. L., Strasser, A., & Cory, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721758

Targeted protein degradation in the digital era: Computational challenges and opportunities for PROTACs

Tewari, A., Pawar, A. B., & Roy, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100372 · Cited by 1

Does the sequence of a disordered protein encode small molecule binding paths?Preprint

Louet, A. A. B., Hummer, G., & Vendruscolo, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726646

Discovery of CRBN ‐based molecular glue degraders targeting WIZ transcription factor

Kim, T., Seong, S., Kim, J., Kwon, T., Kim, H. J., Kim, J., Hwang, J. Y., Cho, J. H., & Choi, K. (2026) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.70182

Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy

Zhang, L., Han, K., Wang, X., Yu, X., Zhang, Y., He, S., Han, Z., Liu, Y., Su, J., Zhou, J., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.8271527

Structure‐Informed Design of Distinct Parallel G‐Quadruplex Stabilizers for KRAS ‐Driven Cancer Therapy

Zhang, L., Han, K., Wang, X., Yu, X., Zhang, Y., He, S., Han, Z., Liu, Y., Su, J., Zhou, J., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.8271527

Biomolecular condensates for proteostasis and potential therapeutic applications

Wen, J., & Li, P. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.06.016

Atomic degradation: chemical design strategies and immunotherapeutic mechanisms of radio-PROTACs

Varol, T. Ö., & Varol, M. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02254-5

Chemical Approaches for Developing Potent Kinase Inhibitors and DNA-Targeting Agents in Cancer Therapy

Bagde, P. H., Deb, B., Shrivastava, H., & Jha, H. C. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_13

HDAC5 depletion promotes hyper-acetylation of FOXA1 and potentiates HIF1α transcriptional activation in pancreatic cancer

Qin, G., Yu, H., Zhao, Y., Xia, W., Qin, Y., Liang, X., Chen, T., Li, Y., Zou, T., Liu, J., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.06.022

Discovery of Stapled Peptide MYC Degrader with Potent In Vivo Activities for Triple-Negative Breast Cancer Therapy

Zhang, N., Li, X., Xu, Y., Jiang, Y., Gao, S., Shen, H., Li, H., Zhang, S., Chi, G., Ma, B., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00442

Molecular Engineering of Stimuli-Activatable Protein Degraders for Precise Cancer Therapy

Gao, J., Lai, Y., Hou, B., Dang, Y., Zhou, H. J., Xu, Z., & Yu, H. (2026) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6c00270

c-Myc: an emerging participant in heart failure

Wu, Y. T., Zhang, J., Liu, R., Lin, W., Wang, W., Zhao, Y. Q., Cai, Y. P., Su, H., Sun, W., Zhu, H., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1832539

Decoding the PI3K/Akt/mTOR-AMPK signalling nexus: molecular crosstalk, metabolic reprogramming and therapeutic targeting in human disease

Yakin, J., Alam, F., & Elpa, J. F. G. (2026) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2026.2710420

Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia

Kumar, A., Hamane, K., Duault, C., Lima-Júnior, J. R., Jung, D. H., Qin, H., Salcido, S., Huang, M., Guo, X., Khani, A. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102945

Chemogenomic sets: valuable tools for early-stage drug discovery

Schoppa, M. Q., & Drewry, D. H. (2026) · Essays in Biochemistry · doi:10.1042/ebc20260007 · Cited by 1

The Long, Remarkable History of KRAS and Pancreatic Cancer: From Gene Discovery to Successful Therapeutic Targeting

Hruban, R. H., & Kern, S. E. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101059

Intracellular protein binders for imaging, control and future therapeutics

Barykina, N. V., & Verkhusha, V. V. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01768-7

Chemical Biology 2025: Highlights From the Ch/Bi145 Course at Caltech

Ashton-Rickardt, G. P., Chung, D. K., Corman, S. A., Gilbert, M. S., Green, Z. B., Hengartner, E. R., Hou, J., Kang, D., Konsler, J. K., Kuleshova, I. D., et al. (2026) · ChemBioChem · doi:10.1002/cbic.70485

Spermidine in Colorectal cancer: friend or foe?

Coni, S., Bordone, R., Campea, L., Ohno, S., Canettieri, G., & Agostinelli, E. (2026) · Amino Acids · doi:10.1007/s00726-026-03554-w

Taking Aim at the Undruggable

Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 59

Targeting the “undruggable” cancer driver genes: Ras, myc, and tp53

WU, X., Pan, D., Tang, S., & Shen, Y. (2023) · Biocell · doi:10.32604/biocell.2023.028790 · Cited by 4

Targeting “undruggable” cancer proteins: pharmacological challenges and emerging strategies

Coelho‐Silva, J. L., Parducci, N. S., Carvalho, M. F. L., Vahedian, V., Lima, K., de Almeida, B. O., & Machado‐Neto, J. A. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1-2830 · Cited by 2

AJS-2 Unlocking undraggable targets: from mission impossible to mission achievable

Spreafico, A. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.011

Drugging Undruggable Molecular Cancer Targets

Lazo, J. S., & Sharlow, E. R. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103440 · Cited by 234